Breast Cancer
Conditions
Interventions
Trial Group ?:The patients received Chinese herbal application intervention at Tianshu (ST25) and Shenque (CV8) acupoints. The application time of the topical plasters is 2–4 hours before chemotherapy
Trial Group ?:The patients received Chinese herbal application intervention at Tianshu (ST25), Shenque (CV8), Zhongwan (CV12) and Xiawan (CV10) acupoints. The application time of the topical plasters
Control Group:Placebo plasters, matching the TCM plasters in appearance, smell and weight without active ingredients, were externally applied at acupoints Tianshu (ST25), Shenque (CV8), Zhongwan (CV12
Sponsors
The Second Qilu Hospital of Shandong University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Individuals with a histologically confirmed diagnosis of primary invasive breast cancer. 2. Female patients aged 18 years and above, scheduled to receive moderate/highly emetogenic chemotherapy (HEC), including but not limited to treatment-naïve patients with early or advanced breast cancer, or patients who had received neoadjuvant or adjuvant chemotherapy more than three months prior to the initiation of first-line chemotherapy for advanced disease, with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2. 3. The administered moderate/highly emetogenic chemotherapy regimens include but not limited to those based on anthracycline in combination with cyclophosphamide, or those based on carboplatin (AUC >= 4) or cisplatin.
Exclusion criteria
Exclusion criteria: 1. Patients scheduled to receive low emetogenic chemotherapy (non-HEC) on Day 1, and those who had received Chinese herbal application therapy for other diseases within 4 weeks prior to the administration of highly emetogenic chemotherapy. 2. Nausea, vomiting, diarrhea or constipation caused by intestinal diseases or malignant tumors; 3. Skin lesions or infections at the selected acupoints; 4. Hypersensitivity to the Chinese herbal powder for acupoint application.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Nausea severity after chemotherapy;Vomiting after chemotherapy;Constipation after chemotherapy;Post-chemotherapy diarrhea; | — |
Countries
China
Contacts
Public ContactZheng Chao
The Second Qilu Hospital of Shandong University
Outcome results
None listed